Edwards Lifesciences Corporation

(New York Stock Exchange)
Back to all articles
Slightly Bullish +15

Edwards Lifesciences Corporation (EW) Stock Forecast (2026)

AI-generated analysis

📉 EW trades at $85.52 as of September 15, 2026, which is in line with CleaRank's fair value but below the Wall Street consensus target of $101.50.

📊 The stock has an RSI of 28, placing it in oversold territory, and is trading below its 50-day average of $89.05.

🚀 Edwards Lifesciences recently beat analyst EPS estimates by 5.41% in the quarter to June 2026.

📈 Revenue growth is projected at 11.00% for the current year, supporting the company's growth narrative in medical devices.

⚠️ Insiders have sold approximately $34 million in stock with no reported purchases, signaling caution.

📉 Technical indicators show bearish short-term momentum as the price remains below its 50-day SMA and 20-day EMA.

🔮 CleaRank's 10-year Monte Carlo simulation projects a base case value of approximately $20,998 for a $10,000 investment by 2036.

Bullish Signals
  • Edwards Lifesciences has a track record of beating analyst EPS estimates, most recently by 5.41% in the quarter to June 2026.
  • The company is projected to achieve 11.00% revenue growth for the current year, indicating continued market demand for its medical devices.
Risk Factors
  • Insiders have sold approximately $34 million in stock with no reported purchases, signaling a degree of caution and potentially limiting near-term upside momentum.
  • The stock is currently trading below its 50-day SMA and 20-day EMA, indicating bearish short-term technical momentum and potential for further price declines.
Full Analysis
As of September 15, 2026, Edwards Lifesciences Corporation (EW) trades at $85.52, which aligns with CleaRank Financial AI's fair value estimate but sits below the Wall Street consensus target of $101.50 set by 29 analysts. The stock is currently in oversold territory with an RSI of 28 and is trading beneath its 50-day average of $89.05, indicating bearish short-term technical momentum. Fundamentally, the company has demonstrated a track record of beating analyst EPS estimates, most recently by 5.41% in the quarter ending June 2026. This consistent outperformance provides a foundation for potential future stock appreciation, while projections indicate the company is expected to achieve 11.00% revenue growth for the current year, reflecting continued market demand for its medical devices. However, insider activity presents a cautionary signal, with insiders having sold approximately $34 million in stock and no reported purchases, potentially limiting near-term upside momentum. While CleaRank's Monte Carlo simulations project various long-term outcomes ranging from a bear case of roughly $5,496 to a bull case near $80,219 by 2036, these are statistical projections based on historical volatility and drift rather than guarantees of future performance.